Episodes of atrial fibrillation can be intermittent or recurring. Although though A-fib is not usually a life-threatening illness, it is a serious medical problem that must be addressed appropriately in order to avoid stroke. Increased product approval and rising incidence of atrial fibrillation are projected to boost the global atrial fibrillation market over the forecast period. On August 24, 2022, physIQ announced a strategic agreement with InCarda Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical firm developing inhaled treatments for cardiovascular disorders. This agreement will hasten the Phase III study in individuals suffering from atrial fibrillation. Product recall is one of the primary issues impeding the growth of the global atrial fibrillation market.
According to Coherent Market Insights, Global Atrial Fibrillation Market is estimated to be valued at US$ 21,042.7 million in 2022 and is expected to exhibit a CAGR of 13.4% during the forecast period (2022-2030).
Market Leaders in the Atrial Fibrillation Industry:
1. AtriCure, Inc.
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices. The company was incorporated in 2000 and is headquartered in Mason, Ohio. On Aug. 12, 2019, AtriCure, Inc. announced that it has entered into a definitive agreement to acquire SentreHEART, Inc., a privately held developer of percutaneous left atrial appendage management solutions.
2. Biosense Webster, Inc.
On Sept. 6, 2022 /PRNewswire/ -- Biosense Webster, Inc., part of Johnson & Johnson MedTech‡, today announced the release of the OCTARAY™ Mapping Catheter with TRUEref™ Technology powered by the CARTO™ 3 Version 7 System. The OCTARAY™ Mapping Catheter was developed for the mapping of cardiac arrhythmias, including atrial fibrillation (AFib).
3. Boehringer Ingelheim GmbH
Boehringer Ingelheim is a research-driven group of companies dedicated to researching, developing, manufacturing, and marketing pharmaceuticals that improve health and quality of life. Our businesses comprise Prescription Medicine, Animal Health, and Biopharmaceuticals. The company was founded in 1885, headquartered in Germany.
4. Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts. On Feb. 15, 2022 Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Baylis Medical Company Inc., a company that offers advanced transseptal access solutions as well as guidewires, sheaths and dilators used to support catheter-based left-heart procedures.
5. Bristol-Myers Squibb Corporation
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. On November 2020, Bristol Myers Squibb Completes Acquisition of MyoKardia, Strengthening Company’s Leading Cardiovascular Franchise
6. CardioFocus, Inc.
CardioFocus is a biotechnology company that focuses on the advancement of ablation treatments for cardiac disorders. The company specializes in providing electrophysiologists with innovative and effective tools that bring new levels of precision and control to the treatment of atrial fibrillation that focuses on developing, manufacturing, and investigating disposable fiber optic catheters for the visualization of the cardiac anatomy and the treatment of cardiac arrhythmias. CardioFocus was founded in 1990 and is headquartered in Marlborough, Massachusetts. On July 19, 2022 CardioFocus, Inc. announced several milestones toward the development of a next generation pulse field ablation (PFA) technology for treatment of AFib, including the formation of a clinical advisory board, filing of key patents and completing initial pre-clinical studies.
7. Endoscopic Technologies, Inc.
Endoscopic Technologies, Inc. doing business as a Estech, provides medical products and services. The Company develops less-invasive surgical tools for the treatment of arrhythmias, particularly atrial fibrillation. Estech serves customers in the United State. The company was founded in 1996, headquartered California, U.S.
8. Sanofi Aventis
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. Sanofi was founded in 1973 and is headquartered in Paris, France.
9. Johnson and Johnson Ltd.
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. On December 22, 2022 – Johnson & Johnson today announced it has completed its acquisition of Abiomed, Inc. Abiomed is now part of Johnson & Johnson and will operate as a standalone business within Johnson & Johnson’s MedTech segment. The company was founded in 1886 and is based in New Brunswick, New Jersey.
10. Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.in June 2017, it is confirmed the announcement by Abbott Laboratories of their acquisition of St. Jude Medical. With this acquisition, Abbott has established itself as a leader in the medical device arena.
*Definition - The atria, the top chambers of the heart that should pulse in rhythm with the ventricles, instead beat erratically and inconsistently when atrial fibrillation develops.
